Press Releases

Loxo Oncology to Present at Upcoming Investor Conferences

STAMFORD, Conn., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that the company will be participating in the following upcoming investor conferences:

  • At the Citi Annual Biotech Conference on September 8, 2016 at 8:00AM ET in Boston, Joshua H. BilenkerM.D., chief executive officer, will be participating in a panel discussion entitled, “Developing Cancer Therapeutics in 2016”
  • At the Morgan Stanley Global Healthcare Conference on September 14, 2016 at 2:10PM ET in New York City, Joshua H. Bilenker, M.D., chief executive officer, will present a corporate overview

Live webcasts of the panel and presentation will be available at http://ir.loxooncology.com/.

About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com

Contacts for Loxo Oncology, Inc.

Company:
Jacob S. Van Naarden
Chief Business Officer
jake@loxooncology.com 

Investors:
Peter Rahmer
The Trout Group, LLC
646-378-2973
prahmer@troutgroup.com 

Media:
Dan Budwick
Pure Communications, Inc.
973-271-6085
dan@purecommunicationsinc.com 

Loxo Oncology, Inc.